L-Dopa and Carbidopa (Sinemet) in the Management of Parkinsonism

Postgraduate Medical Journal - United Kingdom
doi 10.1136/pgmj.51.599.619
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

BMJ

Related search

Adjuvants to L-Dopa for Parkinsonism.

BMJ
1970English

Delayed O-Methylation of L-Dopa in MB-COMT-deficient Mice After Oral Administration of L-Dopa and Carbidopa

Xenobiotica
PharmacologyBiochemistryMutagenesisHealthMedicineToxicology
2017English

Entacapone Improves the Availability of L-Dopa in Plasma by Decreasing Its Peripheral Metabolism Independent of L-Dopa/Carbidopa Dose

British Journal of Clinical Pharmacology
Pharmacology
2002English

Stereotactic Thalamotomy and L-Dopa Induced Involuntary Movement in Parkinsonism

Neurologia Medico-Chirurgica
SurgeryNeurology
1973English

Subcortical Vascular Lesions Predict Functional Recovery After Rehabilitation in Patients With L-Dopa Refractory Parkinsonism

Journal of the American Geriatrics Society
GerontologyGeriatrics
2004English

Von Economo’s Disease and Postencephalitic Parkinsonism Responsive to Carbidopa and Levodopa

Neuropsychiatric Disease and Treatment
2018English

The Structure of L-Mimosine, an L-Dopa Analogue.

Acta Chemica Scandinavica
1973English

The Combination of Lithium and L-Dopa/Carbidopa Reduces MPTP-induced Abnormal Involuntary Movements (AIMs) via Calpain-1 Inhibition in a Mouse Model: Relevance for Parkinson׳s Disease Therapy

Brain Research
NeuroscienceNeurologyDevelopmental BiologyMolecular Biology
2015English

Hypotension Caused by L-Dopa.

BMJ
1970English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy